Burning Rock Announces Full Exercise of Over-Allotment Option in Initial Public Offering
Burning Rock Biotech Limited (NASDAQ: BNR) announced the full exercise of an over-allotment option in its IPO, allowing for the sale of an additional 2,025,000 American Depositary Shares (ADSs) at US$16.50 each. The total offering size now stands at approximately US$281.2 million. The company has a total of 103,804,534 ordinary shares post-offering, including 86,479,686 Class A shares. The IPO is facilitated by underwriters Morgan Stanley, BofA Securities, and Cowen.
- Total aggregate offering size increased to approximately US$281.2 million.
- Continued demand for its ADSs indicates investor confidence.
- Dilution risk for existing shareholders due to the additional ADSs offered.
GUANGZHOU, China, June 22, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (“Burning Rock” or the “Company”) (NASDAQ: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that the underwriters of its initial public offering (the “IPO”) fully exercised their over-allotment option to purchase an additional 2,025,000 American Depositary Shares (“ADSs”), each representing one Class A ordinary share, of the Company at the IPO price of US
Morgan Stanley & Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as representatives of the underwriters for this offering.
A registration statement related to the offering has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective. Copies of the registration statement can be accessed on the website of the SEC at www.sec.gov.
The offering is made only by means of a prospectus forming a part of the effective registration statement. Copies of the final prospectus relating to this offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, New York, NY 10014, via telephone: 1-917-606-8487, or via email: prospectus@morganstanley.com; BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, via email: dg.prospectus_requests@baml.com; and Cowen and Company, LLC, Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 1-833-297-2926, or via email: PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Burning Rock
Burning Rock Biotech Limited (the “Company”), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. The Company’s business consists of (i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and (ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
FAQ
What is the total size of Burning Rock's IPO after the over-allotment option?
How many additional ADSs were sold in Burning Rock's IPO?
What is the IPO price per ADS for Burning Rock?
Who are the underwriters for Burning Rock's IPO?
What does Burning Rock Biotech focus on?
